Benjamin F. Edwards & Company Inc. increased its stake in shares of Chemours Company (The) (NYSE:CC) by 2,138.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,112 shares of the specialty chemicals company’s stock after buying an additional 2,973 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Chemours Company (The) were worth $118,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Financial Architects Inc increased its stake in shares of Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after buying an additional 2,719 shares in the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares in the last quarter. Schroder Investment Management Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at about $156,000. Cypress Capital Management LLC WY increased its stake in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares in the last quarter. Finally, Clean Yield Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at about $167,000. Hedge funds and other institutional investors own 75.23% of the company’s stock.

Shares of Chemours Company (CC) opened at 49.31 on Friday. The stock’s 50 day moving average price is $41.37 and its 200 day moving average price is $37.03. Chemours Company has a 52 week low of $8.62 and a 52 week high of $49.67. The firm has a market capitalization of $9.13 billion, a P/E ratio of 32.25 and a beta of 3.63.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.85 by $0.02. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 EPS. On average, analysts predict that Chemours Company will post $3.31 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be issued a $0.03 dividend. The ex-dividend date is Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.24%. Chemours Company (The)’s dividend payout ratio (DPR) is presently 8.11%.

TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/06/benjamin-f-edwards-company-inc-buys-2973-shares-of-chemours-company-the-nysecc.html.

CC has been the subject of several recent research reports. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Citigroup Inc. increased their price target on Chemours Company (The) from $62.00 to $63.00 and gave the company a “buy” rating in a report on Monday, April 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Chemours Company (The) in a report on Friday, June 16th. BidaskClub upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.50.

In related news, insider Paul Kirsch sold 19,036 shares of Chemours Company (The) stock in a transaction on Monday, June 5th. The shares were sold at an average price of $41.42, for a total value of $788,471.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Erich Parker sold 4,908 shares of Chemours Company (The) stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.